Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis.
Santhera and NIH collaborate to evaluate Catena® in primary progressive multiple sclerosis
Enhancement of axonal potassium conductance reduces nerve hyperexcitability in an in vitro model of oxaliplatin-induced acute neuropathy.
Translating Fatigue to Human Performance.
Complex antibody profiling to predict clinical outcome in childhood ADS.
Genzyme’s once-daily, oral AUBAGIO® approved in Australia for treatment of relapsing multiple sclerosis
Glatiramer Acetate administration does not reduce damage after cerebral ischemia in mice.
Immunological mechanisms underlying delayed-type hypersensitivity reactions to glatiramer acetate.
Neuromyelitis optica: Evaluation of 871 attacks and 1153 treatment courses.
Development of cladribine at Scripps for hairy cell leukemia and current results.
Effect of immunosuppressive cladribine treatment on serum leucocytes system in two-year clinical trial in patients with chronic progressive multiple sclerosis.
Safety Study of Interferon Beta-1a for Acute Stroke
Effect of Natalizumab on Circulating CD4(+) T-Cells in Multiple Sclerosis.
Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD.
Novel MS Drug Offers Good Functional Outcomes
Dietary Fatty Acids Directly Impact Central Nervous System Autoimmunity via the Small Intestine.
Interferon-beta in pediatric multiple sclerosis patients: safety in short-term prescription.
Use of amiloride and multiple sclerosis: registry-based cohort studies.
Phase 4 GI Tolerability Study of DMF in Patients With Relapsing Forms of MS in the US (MANAGE)
Daclizumab discontinue letter for the US market
Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS.
Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone.
Teva and Active Biotech to continue with the development of NERVENTRA® (laquinimod) for multiple sclerosis following confirmation of CHMP opinion
Serum from interferon-β-1b-treated patients with early multiple sclerosis stabilizes the blood-brain barrier in vitro.
Nephrotic Syndrome in a Multiple Sclerosis Patient Receiving Long-term Interferon Beta Therapy.

Pages